MOA | pritelivir HCP

HOVILPRI—A novel mechanism of action designed to address key treatment challenges^1-3

Diagram comparing where nucleoside analogues (acyclovir, foscarnet, cidofovir) and helicase-primase inhibitors such as HOVILPRI act on HSV replication

SCROLL TO VIEW

Not a real patient.

How does HOVILPRI work differently from standard therapy?

Targets the HSV helicase-primase complex, an enzyme essential for HSV DNA replication^1,4

Does not rely on viral thymidine kinase activation and maintains antiviral activity independent of this pathway¹

Demonstrated in vitro activity against HSV-1 and HSV-2 isolates, including strains resistant to nucleoside and nucleotide analogues and foscarnet^1,3,5

HSV, herpes simplex virus; MOA, mechanism of action.

References: 1. HOVILPRI. Prescribing information. Asahi Kasei Therapeutics. 2. Birkmann A, Saunders R. Antiviral Res. 2025;237:106152. doi:10.1016/j.antiviral.2025.106152 3. Birkmann A et al. J Med Chem. 2022;65(20):13614-13628. doi:10.1021/acs.jmedchem.2c00668 4. Chemaly RF et al. Clin Infect Dis. 2025;81(3):593-601. doi:10.1093/cid/ciae638 5. Field HJ et al. Antiviral Res. 2013;100(2):297-299. doi:10.1016/j.antiviral.2013.08.024

Important Safety Information

Warnings and Precautions

Drug Interactions With Acid-Reducing Agents: Concomitant use of HOVILPRI with certain acid-reducing agents may reduce pritelivir exposure, potentially resulting in reduced therapeutic effect and development of resistance. Avoid concomitant use with certain proton pump inhibitors, and stagger concomitant use with H2-receptor antagonists and antacids.

Adverse Reactions: In clinical studies, the adverse reaction (all grades) occurring in more than 5% of participants receiving HOVILPRI was headache, which occurred in 6% and 4% of the HOVILPRI and investigator’s choice participants, respectively.

Drug Interactions:

Pritelivir is a breast cancer resistance protein (BCRP) inhibitor. Co-administration of HOVILPRI with a BCRP substrate may increase the plasma concentrations of the BCRP substrate, which may increase the risk of adverse reactions.

Concomitant use of acid-reducing agents may elevate gastric pH and decrease the systemic bioavailability of HOVILPRI, which may reduce its effectiveness or cause drug resistance to HOVILPRI. Avoid concomitant use with esomeprazole or rabeprazole. Avoid concomitant use with omeprazole or lansoprazole at daily doses above 20 mg, or with pantoprazole at daily doses above 40 mg. Take HOVILPRI at least 2 hours before or 12 hours after H2-receptor antagonists. Take HOVILPRI at least 2 hours before or 2 hours after antacids.

HOVILPRI—A novel mechanism of action designed to address key treatment challenges^1-3

How does HOVILPRI work differently from standard therapy?

Explore clinical trials

Important Safety Information

Indication

HOVILPRI—A novel mechanism of action designed to address key treatment challenges1-3

How does HOVILPRI work differently from standard therapy?

Explore clinical trials

Important Safety Information

Indication

HOVILPRI—A novel mechanism of action designed to address key treatment challenges^1-3